Compare Cassava Sciences Inc (FLNA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs PulteGroup, Inc. — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while PulteGroup, Inc. trades at $113.37 (market cap $21.63B). The key difference: PulteGroup, Inc. is far larger — about 549× Cassava Sciences Inc's market cap, and PulteGroup, Inc. pays a 0.92% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and PulteGroup, Inc. for 91 Days on average.
| FLNA | PHM | |
|---|---|---|
Market Cap | $39.40M | $21.63B |
Volume | 759,018 | 2,324,729 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $142.56 |
52-Week Low | $0.68 | $110.11 |
Typical Hold Time | 37 Days | 91 Days |
Enterprise Value | -$43.28M | $22.04B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
PulteGroup (PHM) trades at $112.33, down 3.25% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with recent earnings misses but maintains solid fundamentals including an 11.47 P/E ratio and 14.9% ROE. Cash flow remains positive at $355 million for 2025, though revenue and margins have softened from 2024 peaks. The company continues dividend payments with a $0.26 quarterly payout scheduled for October 2026.
PHM presents a mixed outlook with attractive valuation metrics offset by near-term headwinds. The consensus price target of $139.80 suggests 24% upside potential, but rising interest rates pose significant risk to housing demand. Investors face tension between Wall Street's bullish price targets and current technical weakness, requiring careful monitoring of Q3 2026 earnings due October 22nd for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
